Today: 9 May 2026
Lam Research (LRCX) slips after report China tightens “50% domestic tools” push
31 December 2025
1 min read

Lam Research (LRCX) slips after report China tightens “50% domestic tools” push

NEW YORK, December 30, 2025, 17:52 ET — After-hours

  • Lam Research shares fell about 1.2% to $173.78, tracking declines in U.S. chip-equipment peers Applied Materials and KLA.
  • A Reuters report said China is requiring chipmakers to source at least 50% of equipment domestically for new capacity approvals.
  • Investors are watching for implementation details and whether waivers hold for advanced production lines.

Lam Research shares were last down 1.2% at $173.78 in after-hours trading on Tuesday, after ranging between $173.51 and $177.26 in the regular session. Applied Materials fell 1.2% and KLA slipped 1.3%, while Dutch rival ASML rose about 0.6%.

The move followed a Reuters report that China is requiring chipmakers to use at least 50% domestically made equipment when building or expanding capacity — a shift that could squeeze foreign tool suppliers. The report said the policy is being enforced through procurement tenders tied to state approvals and is already nudging fabs — semiconductor fabrication plants — toward local suppliers in processes where Lam has been a key provider.

Why it matters now: Lam sits at the center of chipmakers’ capital spending cycles, and China’s self-sufficiency drive targets the same budgets that fund new tools and upgrades. A higher domestic-content bar would raise the risk of market-share erosion in China even where foreign tools remain available.

The policy pressure also lands as Washington tightens and reshapes its own export-control framework around shipments of chipmaking tools into China. Reuters reported earlier on Tuesday that the U.S. approved annual licenses for 2026 allowing Samsung Electronics and SK Hynix to bring chipmaking equipment into their China facilities, replacing broader exemptions that expire on Dec. 31.

Lam sells wafer fabrication equipment — chipmaking tools used to build chips on silicon wafers — including etching systems. Etching removes material from the wafer to carve microscopic circuit patterns.

The stock has now fallen for a second straight session and is about 3.35% below its recent 52-week high of $179.80 set on Dec. 26, MarketWatch data showed. Trading volume was about 5.7 million shares, below its 50-day average of 10.9 million, as the S&P 500 and Dow ended modestly lower.

Investors’ next question is how rigid the 50% threshold becomes in practice. The Reuters report said authorities can allow flexibility where domestic alternatives are constrained, particularly for more advanced production lines.

For Lam, the timing matters because equipment demand is driven by new capacity adds and technology upgrades — exactly where procurement rules bite first. Any acceleration in local substitution would likely show up in order mix and service activity tied to China-based fabs.

Lam’s exposure is heavily international: non-U.S. sales accounted for roughly 93% of revenue in fiscal 2025, a filing showed. That makes policy and spending decisions outside the United States a first-order driver for the stock.

Before the next session, investors will be looking for any additional signals from Beijing on how the rule is applied, and whether other countries’ export rules further reshape what tools can be shipped — and serviced — into China’s fabs.

Stock Market Today

  • AbbVie Stock Evaluation: Undervalued After Recent Pullback or Overpriced?
    May 9, 2026, 10:02 AM EDT. AbbVie's shares fell 4.1% over the past week, trading near $202, yet posting strong returns of 12.8% over one year and nearly 110% over five years. Using a Discounted Cash Flow (DCF) model, Simply Wall St estimates AbbVie's intrinsic value at about $418.78 per share, implying the stock is undervalued by 51.6%. The DCF projects free cash flow growth from $18 billion to $34.3 billion by 2030. However, valuation scores are mixed, with 3 out of 6 points indicating some caution, reflecting investor reassessment amid shifts in healthcare and AI sector opportunities. AbbVie's peers have outperformed it recently, raising questions about its relative appeal. Investors should weigh these factors when considering an entry point for this large-cap pharmaceutical firm.

Latest article

Micron Stock Rally: AI Memory Shortage Sends Market Value Past $850 Billion

Micron Stock Rally: AI Memory Shortage Sends Market Value Past $850 Billion

9 May 2026
Micron Technology jumped over 15% Friday to $746.81, pushing its market value near $853 billion, as investors bet on soaring AI data center demand. The company reported fiscal Q2 revenue nearly tripled to $23.86 billion and net income of $13.79 billion. Micron forecast Q3 revenue of $33.5 billion and expects 2026 capital spending above $25 billion. Sandisk also rose more than 16% on similar demand.
AI stocks today: Meta rises on Manus buy as Nvidia slips and Fed minutes keep rates in focus
Previous Story

AI stocks today: Meta rises on Manus buy as Nvidia slips and Fed minutes keep rates in focus

P&G stock dips after Fed minutes as year-end trading thins — what investors watch next
Next Story

P&G stock dips after Fed minutes as year-end trading thins — what investors watch next

Go toTop